WASHINGTON — The United States registered 983 measles cases through July 2026, the highest annual total in 35 years. The resurgence is straining state public health departments and reigniting debate over federal intervention in vaccination policy. The Centers for Disease Control and Prevention reported 12 outbreaks across nine states, with initial transmission often linked to international travel from regions with lower vaccination rates. The spread threatens the country's measles elimination status, first achieved in 2000.
Merck, the primary manufacturer of the measles, mumps and rubella vaccine, is increasing its lobbying push in Washington. The company spent $3.1 million on federal lobbying in the first quarter of 2026, according to OpenSecrets data, focusing on increased federal funding for vaccine procurement and expanded public health campaigns. The American Medical Association is also pressing for stronger federal immunization support, arguing that a national approach is essential to contain communicable diseases. The united front is aimed at securing congressional appropriations for vaccine distribution and public awareness.
The financial burden of managing outbreaks falls heavily on state and local health systems. A 2024 study by the National Bureau of Economic Research estimated the average public health cost per measles case at $142,000, factoring in investigation, contact tracing and potential quarantines. That cost pressure is driving calls for federal appropriations to shore up state immunization programs and giving states a direct financial incentive to back federal funding initiatives.
President Trump's administration faces pressure to address the escalating crisis. The Department of Health and Human Services is evaluating proposals for emergency funding that would flow directly to states with high case counts. Any such allocation would require congressional approval, setting up a legislative fight over public health spending priorities. The debate pits the immediate need for containment against concerns about federal overreach and states' rights in health policy.
Opposition to broader federal mandates remains strong among some conservative groups and states' rights advocates, who argue vaccine policy should stay under state control, citing concerns about individual liberty and parental choice. The National Vaccine Information Center spent $450,000 on federal advocacy in 2025, targeting any legislation that would strengthen vaccination requirements or preempt state-level exemptions — a lobbying effort that complicates the path for any comprehensive federal public health bill.
